Mitsubishi UFJ Trust & Banking Corp Increases Position in Royalty Pharma PLC $RPRX

Mitsubishi UFJ Trust & Banking Corp lifted its holdings in Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 16.2% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 1,764,269 shares of the biopharmaceutical company's stock after purchasing an additional 245,570 shares during the period. Mitsubishi UFJ Trust & Banking Corp owned about 0.31% of Royalty Pharma worth $68,171,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the business. CWM LLC increased its stake in shares of Royalty Pharma by 1.5% in the 3rd quarter. CWM LLC now owns 18,591 shares of the biopharmaceutical company's stock valued at $656,000 after purchasing an additional 281 shares in the last quarter. Private Trust Co. NA increased its stake in Royalty Pharma by 52.9% during the 4th quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company's stock worth $32,000 after buying an additional 288 shares in the last quarter. Hudson Bay Capital Management LP increased its stake in Royalty Pharma by 1.0% during the 3rd quarter. Hudson Bay Capital Management LP now owns 29,384 shares of the biopharmaceutical company's stock worth $1,037,000 after buying an additional 289 shares in the last quarter. Merit Financial Group LLC increased its stake in Royalty Pharma by 3.5% during the 3rd quarter. Merit Financial Group LLC now owns 9,149 shares of the biopharmaceutical company's stock worth $323,000 after buying an additional 306 shares in the last quarter. Finally, Larson Financial Group LLC increased its stake in Royalty Pharma by 31.9% during the 3rd quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company's stock worth $45,000 after buying an additional 306 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Royalty Pharma Price Performance

NASDAQ:RPRX opened at $49.54 on Wednesday. The company has a current ratio of 2.40, a quick ratio of 2.40 and a debt-to-equity ratio of 0.88. The stock has a 50 day moving average of $47.13 and a two-hundred day moving average of $42.26. The firm has a market cap of $28.58 billion, a P/E ratio of 36.70, a price-to-earnings-growth ratio of 3.17 and a beta of 0.39. Royalty Pharma PLC has a 12 month low of $31.97 and a 12 month high of $50.25.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last posted its quarterly earnings results on Wednesday, February 11th. The biopharmaceutical company reported $1.46 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $1.33 by $0.13. The business had revenue of $621.99 million during the quarter, compared to analyst estimates of $839.97 million. Royalty Pharma had a return on equity of 28.21% and a net margin of 32.38%. On average, analysts expect that Royalty Pharma PLC will post 5.08 earnings per share for the current fiscal year.

Royalty Pharma Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Wednesday, June 10th. Stockholders of record on Friday, May 15th will be given a $0.235 dividend. The ex-dividend date is Friday, May 15th. This represents a $0.94 dividend on an annualized basis and a dividend yield of 1.9%. Royalty Pharma's dividend payout ratio is 69.63%.

Wall Street Analysts Forecast Growth

Several equities research analysts have commented on RPRX shares. UBS Group boosted their price objective on Royalty Pharma from $51.00 to $57.00 and gave the stock a "buy" rating in a research note on Tuesday, April 21st. Citigroup boosted their price objective on Royalty Pharma from $48.00 to $50.00 and gave the stock a "buy" rating in a research note on Tuesday, January 27th. Morgan Stanley boosted their price objective on Royalty Pharma from $61.00 to $63.00 and gave the stock an "overweight" rating in a research note on Friday, April 10th. Weiss Ratings upgraded Royalty Pharma from a "hold (c+)" rating to a "buy (b-)" rating in a research note on Thursday, February 12th. Finally, The Goldman Sachs Group reiterated a "buy" rating on shares of Royalty Pharma in a research note on Thursday, February 12th. Six research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, Royalty Pharma has a consensus rating of "Buy" and an average price target of $50.33.

Insider Buying and Selling

In other news, EVP Marshall Urist sold 20,000 shares of the company's stock in a transaction that occurred on Friday, January 30th. The stock was sold at an average price of $41.09, for a total value of $821,800.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Terrance P. Coyne sold 34,791 shares of the company's stock in a transaction that occurred on Wednesday, April 1st. The shares were sold at an average price of $48.33, for a total value of $1,681,449.03. Following the completion of the sale, the chief financial officer owned 32,916 shares of the company's stock, valued at $1,590,830.28. This trade represents a 51.38% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 367,914 shares of company stock valued at $16,074,774 over the last 90 days. Company insiders own 18.84% of the company's stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company's transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.